Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell CarcinomaMartin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cell Metabolism|July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCCCerise Tang, Amy X Xie, Eric Minwei Liu, et al.
JCO Precision Oncology|July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell CarcinomaRitesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic CorrelatesChung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell CarcinomaMartin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cell Metabolism|July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCCCerise Tang, Amy X Xie, Eric Minwei Liu, et al.
JCO Precision Oncology|July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell CarcinomaRitesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Pageof 15